OrthoPediatrics beats Q1 revenue estimates, raises 2026 outlook

Orthopediatrics

30/04/2026 21:20

Overview

Pediatric orthopedics device maker's Q1 revenue rose 13%, beating analyst expectations

Q1 adjusted EBITDA turned positive and beat analyst estimates

Company raised full-year 2026 revenue guidance, citing broad-based growth and new product launches

Outlook

OrthoPediatrics raises 2026 revenue guidance to $263 mln-$267 mln from $262 mln-$266 mln

Company expects about $25 mln adjusted EBITDA and breakeven free cash flow for 2026

OrthoPediatrics anticipates annual set deployment of about $10 mln in 2026

Result Drivers

TRAUMA & DEFORMITY GROWTH - Co said Q1 revenue growth was driven primarily by organic growth in Trauma and Deformity, Scoliosis and OPSB products

INTERNATIONAL SALES - Co said international revenue rose 22% in Q1, driven by increased procedure volumes and limited set sales

NEW PRODUCTS & CLINIC EXPANSION - Co cited OPSB growth supported by new products and clinic expansion as a driver of momentum in the quarter

Company press release: ID:nGNX2YXSfr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$59.4 mln
$58.32 mln (9 Analysts)
Q1 EPS
-$0.45
Q1 Net Income
-$10.7 mln
Q1 Adjusted EBITDA
Beat
$2.2 mln
$913,630 (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $24.00, about 63.9% above its April 29 closing price of $14.64

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)